These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30789540)

  • 21. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In search of the perfect comorbidity measure for use with administrative claims data: does it exist?
    Baldwin LM; Klabunde CN; Green P; Barlow W; Wright G
    Med Care; 2006 Aug; 44(8):745-53. PubMed ID: 16862036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Effectiveness of Oxaliplatin Versus 5-flourouricil in Older Adults: An Instrumental Variable Analysis.
    Mack CD; Brookhart MA; Glynn RJ; Meyer AM; Carpenter WR; Sandler RS; Stürmer T
    Epidemiology; 2015 Sep; 26(5):690-9. PubMed ID: 26196683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.
    Iwashyna TJ; Lamont EB
    J Clin Oncol; 2002 Oct; 20(19):3992-8. PubMed ID: 12351596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
    Petito LC; García-Albéniz X; Logan RW; Howlader N; Mariotto AB; Dahabreh IJ; Hernán MA
    JAMA Netw Open; 2020 Mar; 3(3):e200452. PubMed ID: 32134464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer.
    Ayvaci MU; Shi J; Alagoz O; Lubner SJ
    Med Decis Making; 2013 May; 33(4):521-32. PubMed ID: 23313932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.
    Weiss JM; Schumacher J; Allen GO; Neuman H; Lange EO; Loconte NK; Greenberg CC; Smith MA
    Ann Surg Oncol; 2014 Jun; 21(6):1781-91. PubMed ID: 24643898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly.
    Neugut AI; Matasar M; Wang X; McBride R; Jacobson JS; Tsai WY; Grann VR; Hershman DL
    J Clin Oncol; 2006 May; 24(15):2368-75. PubMed ID: 16618946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.
    Haller DG; O'Connell MJ; Cartwright TH; Twelves CJ; McKenna EF; Sun W; Saif MW; Lee S; Yothers G; Schmoll HJ
    Ann Oncol; 2015 Apr; 26(4):715-724. PubMed ID: 25595934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.
    Schrag D; Rifas-Shiman S; Saltz L; Bach PB; Begg CB
    J Clin Oncol; 2002 Oct; 20(19):3999-4005. PubMed ID: 12351597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer.
    Murphy CC; Harlan LC; Warren JL; Geiger AM
    J Clin Oncol; 2015 Aug; 33(23):2530-6. PubMed ID: 26150445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer.
    Hanna N; Bikov KA; McNally D; Onwudiwe NC; Dalal M; Mullins CD
    Oncologist; 2012; 17(9):1191-7. PubMed ID: 22767876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of adjuvant chemotherapy on survival benefit in stage III colon cancer patients stratified by age: a Japanese real-world cohort study.
    Kawamura H; Morishima T; Sato A; Honda M; Miyashiro I
    BMC Cancer; 2020 Jan; 20(1):19. PubMed ID: 31906959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data.
    Hanna NN; Onukwugha E; Choti MA; Davidoff AJ; Zuckerman IH; Hsu VD; Mullins CD
    Colorectal Dis; 2012 Jan; 14(1):48-55. PubMed ID: 21689262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis.
    Jiao X; Hay JW; Sadeghi S; Barzi A
    Am J Clin Oncol; 2020 Jun; 43(6):428-434. PubMed ID: 32187027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
    Margalit O; Mamtani R; Yang YX; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
    Eur J Cancer; 2018 Jun; 96():105-110. PubMed ID: 29698932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Completion of therapy by Medicare patients with stage III colon cancer.
    Dobie SA; Baldwin LM; Dominitz JA; Matthews B; Billingsley K; Barlow W
    J Natl Cancer Inst; 2006 May; 98(9):610-9. PubMed ID: 16670386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Effectiveness of Chemotherapy Regimens in Prolonging Survival for Two Large Population-Based Cohorts of Elderly Adults with Breast and Colon Cancer in 1992-2009.
    Du XL; Zhang Y; Parikh RC; Lairson DR; Cai Y
    J Am Geriatr Soc; 2015 Aug; 63(8):1570-82. PubMed ID: 26200214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.